IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Clinical comparison of ibutilide and propafenone for converting atrial flutter
Sun, JL; Guo, JH; Zhang, N; Zhang, HC; Zhang, P
关键词Atrial Flutter Ibutilide Propafenone Conversion Tolerability Arrhythmia
刊名CARDIOVASCULAR DRUGS AND THERAPY
2005
DOI10.1007/s10557-005-6898-y
19期:1页:57-64
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems ; Pharmacology & Pharmacy
研究领域[WOS]Cardiovascular System & Cardiology ; Pharmacology & Pharmacy
关键词[WOS]INTRAVENOUS IBUTILIDE ; ANTIARRHYTHMIC AGENT ; CONVERSION EFFICACY ; CLASS-I ; FIBRILLATION ; TERMINATION ; ARRHYTHMIAS ; SOTALOL ; DRUG ; PROCAINAMIDE
英文摘要

Objective: To evaluate the efficacy and safety of intravenous ibutilide and propafenone for immediate treatment of atrial flutter.

Methods: Forty patients with atrial flutter with an arrhythmia duration of three hours to 90 days were randomized to receive up to two 10-minute infusions of ibutilide (1 and 1 mg) or propafenone (70 and 70 mg) with a 10-minute interval.

Results: Ibutilide was superior to propafenone for treating atrial flutter (90% vs. 30%, p < 0.01). The median conversion time in the ibutilide group was 11 min (the 25th and 75th percentile was 10 and 45 min), and the median conversion time in the propafenone group was 35 min (range 20-55 min). In all patients, the duration of arrhythmia before treatment was a predictor of arrhythmia termination, although this was more obvious in the group that received ibutilide. Conversion of atrial flutter by ibutilide was characterized mainly by increased cycle length variability. Bradycardia (2/20) and hypotension (4/20) were more common side effects with propafenone. Of 20 patients given ibutilide, 8 (40%) who developed monomorphic ventricular extrasystoles or repetitive atrial flutter with aberrant conduction tachycardia, no one required any specific treatment except for the interruption of ibutilide infusion.

Conclusion: Ibutilide is highly effective for rapidly terminating atrial flutter. This new class III drug, under monitored conditions, is a potential alternative to currently available cardioversion options.

语种英语
WOS记录号WOS:000229001300009
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56683
专题北京大学第二临床医学院_心血管内科
作者单位Peking Univ, Peoples Hosp, Dept Cardiol, Electrophysiol Grp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Sun, JL,Guo, JH,Zhang, N,et al. Clinical comparison of ibutilide and propafenone for converting atrial flutter[J]. CARDIOVASCULAR DRUGS AND THERAPY,2005,19(1):57-64.
APA Sun, JL,Guo, JH,Zhang, N,Zhang, HC,&Zhang, P.(2005).Clinical comparison of ibutilide and propafenone for converting atrial flutter.CARDIOVASCULAR DRUGS AND THERAPY,19(1),57-64.
MLA Sun, JL,et al."Clinical comparison of ibutilide and propafenone for converting atrial flutter".CARDIOVASCULAR DRUGS AND THERAPY 19.1(2005):57-64.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, JL]的文章
[Guo, JH]的文章
[Zhang, N]的文章
百度学术
百度学术中相似的文章
[Sun, JL]的文章
[Guo, JH]的文章
[Zhang, N]的文章
必应学术
必应学术中相似的文章
[Sun, JL]的文章
[Guo, JH]的文章
[Zhang, N]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。